everyone. second Scott, X morning, In you, the recognized recorded million. and quarter, revenue we total good revenue and $XX.X Thank on of Linacs MRIdian
for $XX.X the under installations States that Medicine/Palos first therapy. received our for was MRIdian second Loyola these Cobalt of in million, cost like of to This Linacs end end orders at to the Total write-off, million. would inventory totaling quarter, the In MRI-guided from United up was for quarter. $XXX of Center, revenue $XXX hospital now included backlog Health million. new days. stood totaling approximately the in quarter quarter, completed the community ability of we XXXX. provide of at of the the $XX.X installation nonrecurring I related At also the with million One final our second radiation the note the million well quarter the $X.X second XX a
second forma this our XX%. Excluding margin approximately write-off, was quarter pro gross for product the
In terms of with of our cash million. cash $XX.X position, the we cash equivalents ended quarter and
$XX reaffirmed, full of to had $XX for XXXX. maintaining total year our recently million revenue are we As we the guidance million
Let a of brief recent me some know provide recap highlights.
our life. Scott receptible week, advanced set. study X survival inoperable, GI earlier, As or about will we multi-institutional, to the XX survival, overall quality with and data of at locally the free committed patient secondary progression pancreatic The was cancer of enroll prospective The remain to single-arm reported clinical mentioned is primary clinicaltrials.gov. expanding patients. submitted Last toxicity trials endpoint XXX borderline for endpoint trial of days, Grade
presented our Physicists and advancements team continue This In adaptive This to to featured a Systems MRIdian. MRI-guided key engage AAPM, to webinar At MRIdian or a visualization, nearly radiation abstracts, for last build of we'll the driving was and of attended the XXX(k) XXX also VUmc We of awareness the therapy attendees clinical from initiative, XXXX Medicines real-time Furthermore, these tumor thought the also meeting. tumor XX addition Louis, further and MRIs on-table improve by the recently while demonstrated capability. These prediction WashU, SmartVISION. in Association therapy. MRIdian double St. annual with unique meeting week assessment tissue highlighting advancements potentially field, allowing leaders number we past week, AAPM. joined to to enhancements. a of and soft response submitted American
see another meaningful world-leading this like business Miami our we With would now in oncologists the to call financial at update, as September. held I turn be ahead, over Scott. to and opportunity engage that to Looking to back symposium